Faculty-founded company awarded $2 million grant for anticancer treatment
NERx Biosciences, a pre-clinical stage biotechnology company, was awarded a $2 million grant from the National Institutes of Health’s National Cancer Institute to further develop small molecule inhibitors that target the DNA damage response pathway for difficult-to-treat cancers, such as lung and ovarian cancer.